The United Kingdom and the United States have established a major commercial pact that will ensure zero import taxes on British medicine products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to increase expenditure on drugs through the National Health Service (NHS). This move guarantees that import taxes on these crucial exports will remain at nothing for a period of three years.
This deal comes after recent warnings to significantly raise import taxes on patented pharmaceutical imports, with increases discussed up to one hundred percent.
"This arrangement with the UK bolsters the worldwide climate for cutting-edge drugs and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a statement declared.
Trade Importance
Medicines are one of the the United Kingdom's biggest export categories to the US, which is easily the largest buyer for major British pharmaceutical firms.
Export figures show that in the year prior to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that period.
"This agreement safeguards work, boosts funding and paves the way for the UK to establish itself as a international leader for medical research," a minister commented.
Detailed UK Commitments
The pact involves several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates topped twenty percent.
Recent Tensions
The pact takes place against a protracted tension between the sector and the UK government over medicine costs and regulatory access.
The disagreement were heightened by assertions that US patients were charged significantly more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
